Hot Investor Mandate 1: Investment Arm of Major Food Conglomerate Invests in Therapeutics, Medical Devices and Biotech R&D Services

9 Feb

The investment arm of a large food and beverage conglomerate headquartered in Asia invests from a fund of about US$ 500 million. The firm invests in several sectors including healthcare. Typical equity investment ranges from US0.5-5 million in early stage businesses. The firm is open to either leading or following in a financing round. PIDC is currently looking for opportunities from Taiwan, North America, and Europe.

Within healthcare, the firm considers therapeutics, medical devices, and biotech R&D services. In therapeutics, the firm is interested in projects with preclinical or initial clinical validation. The firm takes an opportunistic approach when it comes to medical devices and R&D services. The firm is agnostic to disease areas. Historically, the firm has invested in a specialty pharmaceutical company, a robotic radiosurgery company, and a process R&D and API manufacturing service provider.

The firm is looking for experienced management teams with sector expertise. The firm may request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: